Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
Kentuckiana Cancer Institute
Study ID
NCT00264134
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
  • Irinotecan — DRUG
  • Carboplatin — DRUG

Study Details

Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.

Key Dates

Start date
Jun 30, 2003
Status verified
Jan 2010
Completion
Oct 31, 2005

Study Design

Enrollment
40 participants
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.

Locations (1)

FacilityCityStateZIPSite coordinators
Kentuckiana Cancer InstituteLouisvilleKentucky40202-

Find similar trials in Louisville, KY

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Kentuckiana Cancer Institute· Louisville, KY

Related Studies